Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive: early-phase trial registry
2 of 8 indexed Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 2 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive: 8 US clinical trials tracked, 2 recruiting.
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition chronic-phase-chronic-myelogenous-leukemia-bcr-abl1-positive
OPEN 2 | RECR 25% | LATE 0 | EARLY 8 | RANK #2176 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Abdominal Pain (25% recruiting · 20 trials)
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive lists 2 open slots (25% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive is recruiting below its size-band peers.
2 of 8 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive research.
M.D. Anderson Cancer Center accounts for 4 of 8 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials plan to enrol fewer than 100 people.
Median target enrolment is 81 among the 8 trials that report a genuine target (sentinel values excluded). 5 of those (62.5%) plan for fewer than 100 participants.
-
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive research is mostly interventional.
8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
Personalized NK Cell Therapy in CBT
M.D. Anderson Cancer Center
NCT02727803
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
M.D. Anderson Cancer Center
NCT01746836
Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
NCT02689440
Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant
City of Hope Medical Center
NCT02506933
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
SWOG Cancer Research Network
NCT03654768
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
ECOG-ACRIN Cancer Research Group
NCT03516279
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
City of Hope Medical Center
NCT04060277
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
M.D. Anderson Cancer Center
NCT01428635
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive page
8 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive condition card totals 8 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.